2017
DOI: 10.1159/000472149
|View full text |Cite
|
Sign up to set email alerts
|

Glycemic Control in the Treatment of Psoriasis

Abstract: Psoriasis is a common chronic inflammatory skin disease that manifests as scaly erythematous plaques as a consequence of keratinocyte hyperproliferation and inflammation. It is commonly associated with diabetes, obesity, and the metabolic syndrome. While there are numerous approved treatment options available, they have limitations including availability, toxicities such as immunosuppression, and high cost. There is increasing evidence to suggest that several hypoglycemic agents used in the treatment of type 2… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
28
0
2

Year Published

2017
2017
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 35 publications
(30 citation statements)
references
References 80 publications
0
28
0
2
Order By: Relevance
“…There is increasing evidence to suggest that several hypoglycemic agents used in the treatment of type 2 diabetes, including glucagon-like peptide-1 receptor (GLP-1) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones and biguanides, exert beneficial effects on psoriasis. Within the mechanisms proposed to explain these findings are weight loss, glycemic control and the direct effect on inflammation pathways [98].…”
Section: Hypoglycemic Agentsmentioning
confidence: 99%
“…There is increasing evidence to suggest that several hypoglycemic agents used in the treatment of type 2 diabetes, including glucagon-like peptide-1 receptor (GLP-1) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones and biguanides, exert beneficial effects on psoriasis. Within the mechanisms proposed to explain these findings are weight loss, glycemic control and the direct effect on inflammation pathways [98].…”
Section: Hypoglycemic Agentsmentioning
confidence: 99%
“…Similar to the studies investigating the effect of anti‐inflammatory treatment on insulin resistance, the effects of antidiabetic drugs on psoriasis have been studied on several occasions. Intriguingly, there are a number of reports that treatment with antidiabetic drugs can have positive effects on psoriasis . If that were indeed the case then it would be suggestive of a common pathogenesis.…”
Section: Comments On the Available Evidence From Clinical Studiesmentioning
confidence: 99%
“…The reports cover different antidiabetic treatments, for example glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), dipeptidyl peptidase 4 inhibitors, thiazolidinediones and biguanides. However, a relief of psoriasis symptoms due to antidiabetic drugs has been seen mainly in small studies so far . Two randomized placebo‐controlled studies with a GLP‐1RA and thiazolidinediones failed to show a beneficial effect of antidiabetic drugs on psoriasis.…”
Section: Comments On the Available Evidence From Clinical Studiesmentioning
confidence: 99%
“…Obese psoriatic patients have frequently associated metabolic comorbidities (i.e. DM type 2, Mets, hyperlipidemia) that must be treated with other drugs (polypharmacy), which can complicate treatment [20,27] or present favorable effects on psoriasis severity [27,28]. Indeed, several hypoglycemic agents used in the treatment of DM type 2, including metformin, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors and thiazolidinediones, display simultaneous favorable glycemic and anti-psoriatic effects through targeting skin inflammation networks and keratinocyte proliferation [28].…”
Section: Expert Opinionmentioning
confidence: 99%
“…DM type 2, Mets, hyperlipidemia) that must be treated with other drugs (polypharmacy), which can complicate treatment [20,27] or present favorable effects on psoriasis severity [27,28]. Indeed, several hypoglycemic agents used in the treatment of DM type 2, including metformin, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors and thiazolidinediones, display simultaneous favorable glycemic and anti-psoriatic effects through targeting skin inflammation networks and keratinocyte proliferation [28]. Moreover, statins, particularly simvastatin and atorvastatin, which are commonly used to lower serum cholesterol and CVD risk, may decrease psoriasis severity due to their effects on lipid metabolism as well as their immunomodulatory and anti-inflammatory actions [20,27].…”
Section: Expert Opinionmentioning
confidence: 99%